Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II.
Epistemonikos ID: e40973eddc11aa99757bd9070ee96b58ad9c4f35
First added on: Dec 20, 2023